Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

This will now stabilise at these levels until brokers note comes out.I believe mm's flushing out weak holders so we didn't see our 2.This will come and i'm still here and will be here till we become a global player.Sorry to disappoint you scottie.

You don't disappoint me nematode, on the contrary you're very predictable, just like it was predictable that the price was going to go South after so much mass hysteria on the various bulletin boards. One minute you say you are perplexed by the share movement, and the next minute you try to sound like you know what you are talking about. When I first posted my opinion on this share you told me to "piss off", then you called me a "cretin" - and in the meantime the share price has gone down by ---------- well to be quite honest I've lost track now, perhaps 30p. You really don't have a clue about how MMs make their money, how share prices react before, and, on results days, etc ---- in fact you are just simply clueless. I wouldn't care, as I have no holding in this share, but I really object to the fact that you have ramped this share incessantly for the last few weeks, and some poor suckers might actually have believed you and got dragged into buying. Put that in your ramping pipe and smoke it.

Bullie , I've put your name down for that Barclays sponsored trading seminar.

:-)

Dil; Thanks:-)

Well Scottie,round 1 to you but remember there's another 11 to go,we'll see,in the words of the greatest...Muhammed Ali,"I shall return!!!!"

Added more at 105p. Dil; C'mon down boyo, the price is right.......!

I've added your name to the course list Bones :-)

:)

Dil,

You got ADVFN access yet, mines still not working.

Yes works fine , I've only tried accessing the bb's though.

Try clearing your cache , ctrl + F5 I think.

Sorry nematode, I'm not a boxing fan, I prefer tennis. I thought share bulletin boards were all about trying to make money for your fellow men/women, and enjoying an open debate. How naive of me. You will be pleased to know that I will not be posting on this thread again, irrespective of whether or not this share goes to 2, or 75p. Good luck with your share dealing, and good luck to all the other BPRG holders.

Thanks scottie.Can't understand why as a non holder you bothered in the first instance.I would buy more at these ridiclously low prices Scottie before the leap to 2.00 after the brokers note.

Someone already said that .... at 140p , 130p ,120p ....

Hey Bullie , that was lucky getting in the day before Shares tipped them :-)

Bungalow.

Bought at 106 and 108. It sometimes isn't the theory it is the B. market

PS I think it will go back up to 150-60 in spite of for sale notice in IC

Im sure you are right Fred. All the speculators should be out by now, think it will return to a nice gentle upwards path.

cheers GF.

Found this on another thread this evening,..........The item in question comes from, Weekly market report

analyst@thewrongprice.com.
http://www.thewrongprice.com/


Bioprogress steps up a gear

Bioprogress (BPRG), which is developing novel ways of delivering drugs,
released its first set of final figures since moving from Nasdaq to AIM
last May. The numbers, showing a million loss on turnover of ,000,
were pretty irrelevant compared with two accompanying announcements, which
should transform the group?s fortunes.

Chief executive Graham Hind has pulled off an intriguing deal to buy the
principal assets of Florida-based Aquafilm for an initial $3.5 million and
a possible $7.5 million depending on the performance of the business.

Most of this will be financed by a placing with UK institutions raising
5 million net at 110p a share. At the end of 2003 the company already
had million net cash, so the group now looks more than adequately
funded for the next few years.

More importantly Aquafilm is already producing serious revenues of $4
million annually, thanks to agreements to make edible films for use in
nutritional products, such as vitamins, and food products. The company has
contracts with Boots in the UK to make Vitamin C strips and Wrigleys to
produce breath freshener that dissolves in the mouth.

Hind?s plan is to upgrade the facility so that soluble films for use by
drug companies can be made there as well. This should fast track
BioProgress?s business plan, which is either to produce in-house these
novel delivery systems replacing tablet doses, or else licence out its
technology.

On that front the group also revealed that it has signed a global licensing
deal with one of the world?s leading producer of over-the-counter medicines
and nutritional items, using its Xgel Tabwrap technology. This will replace
traditional tablets with non-gelatin wrapped drugs that will dissolve far
quicker.

The shares, which joined AIM at 16p before shooting up on exceptionally
heavy trading to 164p, lost nearly a quarter of their value this week to
end at 112.5p. This is slightly above the institutional placing price and
values the group at around million. The latest deal lowers the stock?s
risk without reducing its growth potential. Buy

I am still holding only wish I could afford more, thanks for the info GF.

March, UK-based, BioProgress has executed an exclusive licensing agreement for its Xgel Tabwrap dosage form technology with a US pharmaceutical company which is a global leader in the OTC medicines and Nutritionals (vitamins, minerals and supplements) product sectors.

The US pharmaceutical company, which remains confidential, has acquired an exclusive license for Tabwrap, one of the BioProgress Xgel dosage forms in a specific market sector and for the territory of North America and the European Union.
BioProgress will receive a payment of US$900,000 upon the first commercialisation and a royalty based on the licensee's sales price of all products which use the Tabwrap dosage form. The Tabwrap technology will initially be applied to a limited number of products which could be on sale before the end of 2005. Sales of the initial group of products, when fully introduced to the US market, are expected to generate royalty income for BioProgress of between $1m and US$1.5m per year. That amount could grow significantly as the Tabwrap technology is applied to higher volume products, new products and introduced into the European market in competition with old tablet coating technology.

The Tabwrap machines will be manufactured under license by the licensee and films for Tabwrap may be supplied to the licensee from the newly acquired BioProgress cGMP film facility in Tampa, Florida USA, generating further revenues and profits for the company.

To ensure that there is the security of multiple supply sources for film in North America, the US pharmaceutical company will also establish a pharmaceutical standard (cGMP) film manufacturing facility to supply their own film requirements under the exclusive license. This second facility will also exclusively supply BioProgress with film, giving BioProgress guaranteed additional cGMP film capacity in the USA as film requirements grow for all BioProgress technologies and customers in the North American market.

BioProgress CEO Graham Hind, said: 'Tabwrap is a technology designed to replace traditional tablet coating techniques by providing a non-gelatin lower-cost, faster, more efficient process. We can also manipulate the dissolution rate of the Tabwrap coating film to increase the dissolution rate of the tablet and add value to products by making the tablet active available to the body faster and facilitating a "faster acting" claim. It also enables a two-colour tablet product presentation not possible with traditional tablet coating methods, offering further product differentiation and marketing advantages over current tablet coating processes. As the Tabwrap film is made from already approved materials and the tablet cores remain unchanged, the regulatory issues are minimal and the technology adoption time and product time to market is relatively short.

'According to IRI, an independent pharmaceutical market monitor, the OTC medicines market in the US is valued at $10.8bn per annum. The European market is also extremely substantial. If our licensee is successful in securing even a modest share of this marketplace through Tabwrap, it is not unrealistic to anticipate that within a few years the BioProgress royalty stream on Tabwrap alone will be very SIGNIFICANT.'